Tomorrow Investor

XTEND Wins $3M Contract for 100 XOS-Enabled Robotic Drone Systems in Asia-Pacific

XTEND Secures $3M Contract for 100 XOS Drone Systems | GlobeNewsWire

Significant Asia-Pacific Contract to Date Expands XOS Deployment Footprint and Strengthens International Orders Backlog TAMPA, Fla., June 09, 2026 (GLOBE NEWSWIRE) — JFB Construction Holdings (Nasdaq: JFB) announced today that  XTEND , a leader in software systems and artificial intelligence-powered robotics, has secured a multi-million-dollar strategic defense contract for the delivery more than 100 Scorpio drone systems powered by XOS, XTEND’s operating system for autonomous robotics, to a defense customer in the Asia-Pacific region.

This excerpt is quoted from the original release. Read the full announcement on GlobeNewsWire.

Brief Summary

XTEND has achieved a substantial milestone by winning a $3 million contract for the delivery of over 100 Scorpio drone systems powered by XOS. This victory marks a significant expansion in the company’s deployment footprint within the Asia-Pacific region and highlights the increasing international demand for innovative robotics technology.

  • $3M contract for 100 Scorpio drones
  • Major expansion in Asia-Pacific market
  • Enhancement of international orders backlog
  • XTEND’s strength in autonomous tech continues to grow

Why it matters: This contract not only strengthens XTEND’s market position but also attests to the growing need for advanced defense technologies, making it a pivotal moment for investors.

Read the Full Article

This is a summary of the press release. For the complete article and any additional details, please visit the original source.

Read Full Article

Attribution: Original press release by GlobeNewsWire on . We provide an AI-generated summary and links for convenience. Always verify details with the original source. Not investment advice. For informational purposes only.

Tomorrow Investor
The Tomorrow Investor

Markets research for retail investors

Independent coverage of small-cap equities, biotech catalysts, and emerging market opportunities.